Access Insights 2023: Andrew Brownlee Discusses Things to Expect in his "340B Lessons from the Field" Presentation
Berkeley Research Group Director discusses what to expect at his upcoming session.
In an interview with Pharmaceutical Commerce editor Nicholas Saraceno, Andrew Brownlee, director, Berkeley Research Group, discusses what viewers can expect during his breakout session at Access Insights 2023.
Brownlee: What we'll be covering in the session tomorrow is an examination of how stakeholders have reacted to different changes in the 340B program. It's 30 years old now at this point. There have been quite a few in-function points throughout that time period. Particularly over the last three years, as the program has evolved at an increasingly rapid pace we'll be looking at how different stakeholders in the program have been reacting to those changes.
Newsletter
Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.
How Industry Stakeholders View Medicare Advantage Expansion for Patients with Kidney Disease
July 7th 2025A qualitative study explores how MA plan leaders, kidney care managers, and dialysis providers perceive the benefits, risks, and marketing practices surrounding MA enrollment for patients with end-stage kidney disease.
Multi-Indication Drug Branding in Today’s Pharmaceutical Industry
July 2nd 2025As drug development increasingly targets multiple indications, pharma companies must make strategic branding decisions—balancing regulatory requirements, market dynamics, and patient safety—to choose between single-brand or multi-brand approaches.
